Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18450%2F18%3A50014812" target="_blank" >RIV/62690094:18450/18:50014812 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/18:10382142
Result on the web
<a href="http://dx.doi.org/10.2174/1567205015666180813150703" target="_blank" >http://dx.doi.org/10.2174/1567205015666180813150703</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1567205015666180813150703" target="_blank" >10.2174/1567205015666180813150703</a>

Result language
angličtina
Original language name
Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Original language description
Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-beta (A beta) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10401 - Organic chemistry

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)